The NOVONORM (repaglinide/Novo Nordisk) brand, founded in 1998 (Denmark), from 307 sister brands and 2214 competing brands. NOVONORM (repaglinide/Novo Nordisk) is owned by NOVO-NORDISK A/S, listed on the stock exchange of Francfort NOVONORM (repaglinide/Novo Nordisk) belongs to the Biotechnology business sector.
Investment simulator :
Portfolio valuation
NOVO-NORDISK A/S
(NOVONORM (repaglinide/Novo Nordisk))
over 5 years*
EUR 641.20